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Abstract 
Cell-based assays are central to life science research. In many cases, these assays require 
transient, or stable, transfection of an exogenous DNA of the cells under study. Previous studies 
examining transcriptional regulation mediated by the tumor suppressor, p53, identified several 
putative p53-regulated promoters involved in diepoxybutene (DEB)-induced cancer progression. 
However, due to potential differences in transfection efficiencies among different promoter 
constructs, a direct comparison of these promoters was difficult to assess. Therefore, we sought to 
develop a generalizable normalization method that would enable direct comparison of promoter 
activation regardless of transfection efficiency. Specifically, we aimed to use GFP co-transfection 
as a means of normalizing the signal from transient transfection of a luciferase-based reporter 
system in TK6 B cells.  We focused primarily on cationic lipid-based transfection reagents because 
1) they have been widely used to transfect a variety of cell types, 2) they cause less stress on the 
cells than electroporation, 3) they are safer and faster than viral transduction, and 4) they are more 
cost effective than specialized transfection methods, such as nucleofection. In this study, we 
conducted a comparative analysis of the liposome-based transfection reagents, Metafectene Pro, 
Lipofectamine 2000, Turbofect, and PEI, as well as nucleofection, which is an alternative 
transfection method based on electroporation. Co-transfection with plasmids encoding luciferase 
and GFP was achieved using the optimized conditions. These studies demonstrate that GFP co-
transfection is an effective means of normalizing for differences in transfection efficiency using 
luciferase-based reporters. 
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Chapter 1 
Introduction 
  Cell-based assays, which include assays designed to assess various aspects of cellular 
physiology such as the cytotoxicity of drugs and environmental factors, the rate of cell 
proliferation, the induction of apoptosis, and the regulation of cellular signaling pathways, are 
central to life science research (Alberts 2002). In many cases, cell-based assays require transient 
or stable transfection of the cells under study. For instance, to measure the regulation of gene 
expression in different cellular contexts, a variety of transcriptional reporter systems have been 
developed (Ataei, Torkzadeh-Mahani et al. 2013).  Transcriptional reporter systems are composed 
of a promoter and/or other transcription factor binding sites placed upstream of an easily detectable 
gene product (i.e. the reporter gene).  
While, in theory, the reporter gene can code for any protein whose activity and/or 
abundance can be measured biochemically, in general, proteins that can be directly detected via 
fluorescence, such as green fluorescent protein (GFP) family members, or whose enzymatic 
activity can be easily monitored via colorimetric or luminescence measurements, such as -
galactosidase or luciferase, respectively, are used (Shagoshtasbi, Deng et al. 2015). In these 
systems, transcriptional activation of the promoter drives the expression of the reporter gene, 
whose relative levels are measured using one of the aforementioned methods. By placing different 
promoters upstream of a given reporter gene, the same assay can be used to compare differences 
in transcriptional activity at various promoters (Reisner, Brauer et al. 2012). 
Previous studies examining transcriptional regulation mediated by the tumor suppressor 
p53 identified several putative p53-regulated promoters involved in diepoxybutene (DEB)-
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induced cancer progression (Akamu and Muganda, personal communication). However, due to 
potential differences in transfection efficiencies among different promoter constructs, a direct 
comparison of these promoters was difficult to assess. Therefore, we sought to develop a 
generalizable normalization procedure that would enable direct comparison of promoter activation 
regardless of transfection efficiency. Specifically, we used GFP co-transfection as a means of 
normalizing the signal from transient transfection of a luciferase-based reporter system in TK6 B 
cells.  During these studies we focused primarily on cationic lipid-based transfection reagents 
because 1) they have been widely used to transfect a variety of cell types (Moghimi, Symonds et 
al. 2005), 2) they cause less stress on the cells than other transfection methods, such as 
electroporation, 3) they are safer and faster than viral transduction, and 4) they are more cost 
effective than specialized transfection methods, such as nulceofection (Lonza).  
In this study, four commercially available transfection reagents, Lipofectamine 2000 (Life 
Technologies), Metafectene Pro (Biontex-USA), Turbofect (Life Technologies), and linear 
polyethylenimine (PEI; Polysciences), were analyzed for their ability to effectively transfect TK6 
B cells while maximizing the fluorescence and luminescence signals. We then developed a 
generalizable normalization protocol that allows comparisons to be made between co-transfected 
cells regardless of transfection efficiency or luminescence intensity.  
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Chapter 2 
Literature Review 
2.1 Luciferase 
The emission of light in a biological system stimulated by an enzyme catalyzed 
biochemical reaction is known as bioluminescence. Due to their low background signal, on the 
one hand, and their potential for enzymatic amplification of the signal, on the other, 
bioluminescence approaches have the potential to be more sensitive than similar fluorescent or 
radionucleotide-based approaches (De, Loening et al. 2007).  For most bioluminescent organisms, 
luminescence is achieved by the oxidation of a luciferin substrate by a family of enzymes known 
as luciferases.  Since luciferases couple each oxidation reaction to the emission of a single photon 
of light, their activity can be measured effectively by photon counting (Leitão and Esteves da Silva 
2010). As a consequence, luciferases have found utility in biotechnology and biomedical research 
as fusion tags and reporter enzymes. 
Most commercially-available luciferases are derived from either luciferases encoded by 
the firefly, Photinus pyralis, or by those encoded by the sea pansy, Renilla reiniformis.  Nano-
luciferase (Nluc) is a newly developed Renilla luciferase (Rluc) variant with the brightest 
bioluminescence reported to date. Nluc exhibits an approximately 150-fold increase in 
luminescence compared to other firefly (Fluc)- or Rluc-based luciferases that have been similarly 
configured for glow-type assays. The Nluc enzyme is very stable, retaining its activity following 
incubation up to 55 °C or in culture medium for >15 h at 37 °C.  Importantly, Nluc utilizes the 
luciferin, coelenterazine, as its substrate. This improves its utility as a bioluminescent tag, since 
5 
 
the conversion of coelenterazine to coelenteramide is achieved in an ATP-independent manner, 
requiring only molecular oxygen as a co-factor (Kucharikova, Vande Velde et al. 2015). 
Due to its stability and robust signal, Nluc has proven to be an effective reporter enzyme 
in transcriptional reporter systems. These systems may be configured to either achieve maximum 
sensitivity or, by appending a degradation sequence to reduce intracellular accumulation, to 
measure dynamic changes in promoter activity (Hall, Unch et al. 2012).  Indeed, reporter 
quantitation can be achieved even at very low expression levels, which allows more reliable 
coupling with endogenous cellular processes. Like Nluc and other luciferases, green fluorescent 
protein (GFP) color variants are also effective intracellular reporters. Importantly, GFP 
fluorescence provides an orthogonal detection method to luminescence, which, as we discuss 
below, can be used to normalize the luciferase signal in co-transfected cells. 
2.2 Green Fluorescent Protein (GFP) 
GFP is a well-established tool for non-invasive and real-time studies in living cells. 
Aequorea victoria GFP is the founding member of a large family of autofluorescent proteins 
isolated from bioluminescent marine organisms, including hydrozoa and reef-building corals of 
the class Anthozoa (Shimomura 2008). A. victoria GFP generates a highly fluorescent p-
hydroxybenzylidene-5-imidizolinone (p-HBI) species from the tripeptide, Ser65-Tyr66-Gly67. It 
is believed that once the polypeptide chain has folded into a near-native conformation, it undergoes 
a series of autocatalytic posttranslational modifications to generate the mature fluorophore 
(Sample, Newman et al. 2009). This process is generally described by a three step mechanism 
consisting of: (1) internal cyclization of Ser65 and Gly67; (2) dehydration to form an imidizolin-
5-one intermediate and (3) dehydrogenation along the C-C bond of Tyr66 to conjugate the ring 
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systems. Dehydrogenation is mediated by molecular oxygen and constitutes the rate-limiting step 
during fluorophore formation. 
The molecular cloning of GFP cDNA and the subsequent expression of GFP as a functional 
transgene has revolutionized biological research, opening profitable avenues of investigation in 
cell, developmental and molecular biology (Voss, Larrieu et al. 2013).  Over the last twenty years, 
A. victoria GFP has been optimized for efficient use in mammalian cells. GFP optimization, 
coupled with improvements in fluorescence detection techniques and quantification, has 
dramatically impacted cell developmental and molecular biology research (Ekberg, Amaya et al. 
2011). Indeed, genetically-encoded FP tags have become the basis for a wide range of cell-based 
applications, including assays designed to assess cytotoxicity, cell proliferation, and the initiation 
of apoptosis. 
2.3 B Lymphocytes  
B cells belong to a group of white blood cells known as lymphocytes, making them a vital 
part of the immune system—specifically the humeral immunity branch of the adaptive immune 
system (Alberts 2002). The principal functions of B cells are to produce antibodies against foreign 
antigens and to develop into memory B cells after activation by antigen interaction (Mauri and 
Bosma 2012).  
TK-6 B cells, which were originally isolated from a patient with chronic myelogenous 
leukemia, are most often used to study mechanisms underlying mutation and to analyze the 
genotoxicity of diverse xenobiotics in B cells (Schwartz, Jordan et al. 2004). Like most cells, TK-
6 B cells undergo apoptosis.  
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B cells are regarded for their capacity to produce antibody but, recent advances in B cell 
biology have capitalized on previous findings and demonstrated that B cells also release a broad 
variety of cytokines (Mauri and Bosma 2012). These cytokines activate specific caspases and 
downstream pathways. Some of these caspases restrain the excessive inflammatory responses that 
occur during autoimmune diseases or can be caused by unresolved infections.  
2.4 Transfection Methods Comparison and Transfection Reagents 
Transfection is the process by which exogenous nucleic acid polymers are introduced into 
cells.  There are four primary methods of transfection: viral, particle-based, non-chemical, and 
chemical-based. Among chemical-based transfection methods, cationic lipid-mediated 
transfection remains one of the most widely used in biomedical research.  Cationic lipid-based 
transfection is believed to occur via a three step process involving 1) interaction of the cationic 
head-groups of the lipids with the negatively-charged backbone of the DNA, 2) endocytosis, and 
3) escape from the endosome and subsequent incorporation into the nucleus following M-phase of 
the cell cycle (Mortimer, Tam et al. 1999).  
Meanwhile, electroporation or electropermeabilization, is a technique in which an 
electrical field is applied to cells in order to increase the permeability of the cell membrane, which 
in turn, allows genes, drugs, or DNA to be introduced into the cell. Nucleofection is a specialized 
electroporation-based transfection method that transfers nucleic acids, such as DNA and RNA, 
directly into the nuclei of cells through the application of a specific voltage program in the presence 
of specialized buffer systems. Despite superior transfection efficiency and cell viability in many 
cases, the high cost of nucelofection has discouraged the wide-spread adoption of this new 
technology (Kang, Ramu et al. 2009).    
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2.4.1 Cationic liposome 
Cationic liposomes are structures that are composed of positively charged lipids and are 
increasingly being researched for use in gene therapy due to their favorable interactions with 
negatively charged DNA and cell membranes (Safinya, Ewert et al. 2014). They can be 
administered efficiently, safely, and repeatedly for direct gene transfer.  Liposomes are vesicular 
structures that can form via the accumulation of lipids interacting with one another in an 
energetically advantageous manner.  Liposomes are generally formed by the self-assembly of 
dissolved lipid molecules, each of which contains a hydrophilic head group and hydrophobic tails. 
These lipids take on associations which yield entropically favorable forms of low free energy, in 
some cases forming bimolecular lipid leaflets. These leaflets are characterized by hydrophobic 
hydrocarbon tails facing each other and hydrophilic head groups facing outward to associate with 
aqueous solution (Hattori, Hara et al. 2015).  Liposomes can exhibit a range of sizes and 
morphologies upon the assembly of pure lipids or lipid mixtures suspended in an aqueous medium 
(Leduc, Wong et al. 2007). 
2.4.2 Lipofecatamine 2000 
Lipofectamine 2000 is a common transfection reagent used in molecular and cellular 
biology (Dalby, Cates et al. 2004).  It is used to increase the transfection efficiency of RNA or 
plasmid DNA into in vitro cell cultures (Dalby, Cates et al. 2004).  In non-dividing cells, research 
has shown that Lipofectamine 2000 improves the efficiency of transfection, which suggests that it 
additionally helps the transfected genetic material penetrate the intact nuclear envelope (Dalby, 
Cates et al. 2004).   
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2.4.3 Metafectene Pro 
Metafectene Pro, which is purported to be more stable than Lipofectamine 2000, utilizes a 
specifically designed molecular structure to ensure easy entry of DNA/RNA into cells. This is 
achieved by condensing DNA/RNA into compact structures (DNA/RNA/lipid-complex) and 
through endosome buffering.  Importantly, metafectene provides persistent expression of the 
introduced gene. This is beneficial to the production of recombinant proteins and also with the 
analysis of downstream long-term effects of DNA expression (Iczkowski, Omara-Opyene et al. 
2004). Metafectene Pro brings an equilibrium point for transfection efficiency, which makes it the 
best candidate for transfection of the co-transfection of GFP- and Luciferase-encoding plasmids 
into B-cells.  
2.4.4 Turbofect 
Turbofect is a new generation of transfection reagent optimized for nucleic acid delivery 
into eukaryotic cells (Lee, Kaul et al. 2014). Its base formulation is similar to the cationic lipids 
described above but it also contains, histone proteins.  This lipid/protein blend allows for slower 
cell membrane penetration that leads to efficient transfection with reduced toxicity (Martin-
Montanez 2010). It also has simple application, working well in media containing antibiotic and 
antimycotic agents. It is ideal for serum containing media; no requirement for media changes.   
2.4.5 Polyethylenimine (PEI) 
Among cationic polymers, polyethylenimine (PEI) is the most popular synthetic polymer 
and has a high cationic charge density (Kang, Tachibana et al. 2010). Polyethyleneimines are used 
in the cell cultures of non-adherent cells to increase attachment, in turn increasing transfection 
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efficiency.  However, it is extremely efficient and also is very cost effective (Moghimi, Symonds 
et al. 2005).   
2.5 Nucleofection 
Nucleofection is a transfection method designed to transfer genes into cells quickly and 
efficiently. The technology is based on electroporation (Muyderman, Yew et al. 2010). The 
Nucleofector device is essentially a cell electroporator that is programmed with various profiles 
that are defined electrical parameters for specific cell types. Each cell type is introduced to the 
DNA (or RNA) in an optimized Nucleofector solution that has been designed for that particular 
cell type (Kang, Ramu et al. 2009). Since the solutions and the programs are pre-configured by 
Lonza, there is little optimization by the user. The only variable that exists in the beginning is 
tittering the amount of nucleic acid that achieves the optimum results, in turn gene expression is 
achieved in as little as a few hours. 
As opposed to most transfection methods, nucleofection introduces the genetic material 
straight into the nucleus where it is assimilated into the cell independent of cell division. This is 
advantageous in that it reduces assay time to a couple of hours as opposed to 24 to 48 hours for 
standard transfection methods using lipid-based reagents. For instance, expression of proteins is 
achieved in as little as 4 hours using primary T cells (Zhao, Su et al. 2011). 
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Chapter 3 
Methodology 
3.1 Transfection Reagents 
Lipofectamine 2000 and Opti-MEM serum were purchased from Life Technologies; 
Metafectene was purchased from Biontex USA; Turbofect was purchased from Thermo Scientific; 
Polyethylenimine (PEI) was purchased from PolySciences. All cationic lipid transfection reagents 
were stored at -20 °C, except for Turbofect and Lipofectamine 2000, which were stored at 4 °C.  
The nucleofection system and buffers are from AMAXA and were stored according to the 
manufacturer’s protocol.   
3.2 Cell Culture 
TK6 B cells were a gift from Perpetua Mubweri Muganda, Ph.D.  The cells were cultured 
in RPMI-1640 medium supplemented with 10% heat-inactivated fetal bovine serum (FBS; Atlanta 
Biologicals) at 37 °C in a CO2 incubator.  Passaging was carried out every 36-48 hours.  Total cell 
count was maintained between 0.5-1.1 x 106 cells/mL.  Cell viability and total count was manually 
measured using Trypan blue staining and a standard hemocytometer. 
3.3 Plasmids and DNA 
The pNL1.1 plasmid was obtained from Promega and derivatized by Jude Akamu (Ph.D. 
candidate in Dr. Muganda’s lab) by the insertion of a strong cytomeglia virus (CMV) promoter 
upstream of the Nluc gene to generate the plasmid, pCMV-LnL1.1. The plasmid encoding GFP-
Max was also kindly provided by Perpetua Mubweri Muganda, Ph.D.  All plasmids were purified 
using the DNA Wizard midi-prep kit (Promega), stored at -20 °C and thawed at room temperature, 
as necessary. 
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3.4 Transfection using Cationic Lipid-based Transfection Reagents 
Approximately 24 hours before transfection, cells were passaged at a density of 0.2 x 106 
cells/well in RPMI-1640 media supplemented with 10% heat-inactivated FBS into a 6-well tissue 
culture dish (Greiner) and incubated at 37°C under 5 % CO2. All cationic lipid-based transfections 
were done in a similar manner, according to the manufacturers’ protocols. Briefly, Transfection 
Solution A was prepared by diluting 2 µg of plasmid DNA into Opti-MEM serum to a final volume 
of 100 µL.  Likewise, Transfection Solution B was prepared by diluting the appropriate volume of 
transfection reagent with Opti-MEM serum to a final volume of 100 µL. Transfection Solution A 
(containing DNA) was then added to Solution B (containing reagent) and mixed gently by 
manually pipetting a couple of times. The combined A/B transfection mixture was then incubated 
at room temperature for 15-20 minutes. The DNA to transfection reagent ratio (DNA:Reagent) 
ranged from 3:1 to 1:3, as indicated. Following incubation, the transfection mixture, containing 
DNA-lipid complexes, was added drop-wise to the cells.  Cells were then incubated at 37 oC under 
CO2 for 24-48 hours, as indicated. Transfected cells were imaged using a Olympus fluorescence 
microscope (see Section 3.6) while luminescence and total GFP fluorescence were measured using 
an Infinite M200 Pro multimode microplate reader (Tecan, USA) using bottom read modes (see 
Section 3.7).  
3.5 Transfection using the Nucleofection System 
Nucleofection was done using either an AMAXA 4D or 2D system, according to the 
manufacturer’s protocol.  In each case, cells were diluted to a density of 0.7 x 106 cells/mL and 
pre-
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program, DS-137. Cells were visualized and assayed 24 and 48 hours after nucleofection, as 
indicated.  
3.6 Fluorescence Microscopy and Calculation of Transfection Efficiency 
 Twenty-four to forty-eight hours following transfection, fluorescent cells were visualized 
using an Olympus 1X71 inverted epifluorescence microscope using the GFP filter set (Ex: 469 
(35); Em: 525 (39)). In a similar manner, the total number of cells were counted by bright field. 
The transfection efficiency was then calculated according to the equation: 
Transection Efficiency = (fluorescent cells/total cells) x 100% 
3.7 Total Fluorescence and Luminescence Measurements  
3.7.1 Total fluorescence measurements 
 Before measuring GFP fluorescence, liposome treated cells were pelleted at 500 x g for 2 
minutes, washed once in Hank’s Balanced Salt Solution (HBSS) imaging buffer and pelleted again. 
The cells were then gently re-suspended in 100 µl of HBSS imaging buffer and transferred to a 
Bio-One black-walled, flat bottom transparent polystyrol 96-well tissue culture dish (Greiner). 
Total fluorescence in each well was measured using an Infinite M200 Pro multimode microplate 
reader. The settings used to measure GFP fluorescence are summarized in Table 1.  
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Table 1:  Fluorescence measurement settings on Infinite M200 PRO 
 
3.7.2 Luciferase Assay 
After measuring total fluorescence, total luminescence was measured using the Nano-Glo 
luciferase assay system (Promega), according to the manufacturer’s protocol. Briefly, cells were 
centrifuged again at 500 x g and re-suspended in 100µl of Nano-Glo luciferase buffer containing 
the coelentrazine substrate. Cells were then incubated for 10 minutes at room temperature followed 
by luminescence reading on the Infinite M200 Pro system. The settings used to measure 
luminescence are summarized below: 
Table 2:  Luminescence measurement settings on Infinite M200 PRO 
Attenuation None 
Integration Time 100 ms 
Settle Time 0 ms  
 
 
 
Excitation wavelength 483 nm
Excitation bandwidth 9 nm
Emission wavelength 535 nm
Emission bandwidth 20 nm
Gain Optimal
Number of flashes 10 flashes
Integration time 20 µs
Lag time 0 µs
Settle time 0 µs
15 
 
3.8 Normalization of Luminescence Signal 
 The luminescence signal was normalized using fluorescence intensity according to the 
following equation: 
LN,i = (Ls,i – Lcont)/(Fs,i-Fcont) 
where LN,i is the normalized luminescene signal, Ls,i is the luminescence intensity of sample i, Lcont 
is the luminescence intensity of the untransfected control cells, Fs,i is the fluorescence intensity of 
sample i, and Fcont is the fluorescence intensity corresponding to untransfected controls.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
16 
 
Chapter 4  
Results 
4.1 Optimization of Transfection and Detection Conditions in B Lymphocytes.  
To optimize the detection conditions using the microplate reader format, TK-6 B cells were 
first transfected with pGFP-Max using a previously developed Metafectene-based transfection 
protocol (Akamu and Muganda, personal communication). The fluorescence of transfected cells 
was then measured under different imaging conditions. To this end, transfected cells were first 
assayed in RPMI-1640, 10% FBS culture medium (containing the pH indicator, phenol red) before 
being pelleted, re-suspended in an equivalent volume of HBSS imaging buffer, and re-measured 
(Figure 1). These experiments suggest that the culture media contributes a large amount of 
background fluorescence compared to the HBSS imaging buffer. Indeed, reading the cells in HBSS 
imaging buffer causes a substantial reduction in background which, in turn, increases the dynamic 
range of the assay (Figure 1).). 
  
Figure 1. Fluorescence read optimization (RPMI vs Imaging Buffer). B cells were transfected with 2 
µg of plasmid DNA encoding GFP-max using Metafectene Pro. The ratio of DNA to transfection reagent 
was 1:3 (2 µg: 6 µl). Each bar represents the average of at least three independent experiments. Error bars 
represent standard error. 
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Next, to determine whether co-transfection with GFP-Max could be used to normalize the 
luminescence signal produced by NLuc under the control of the strong CMV promoter (pCMV-
LnL1.1), pGFP-Max was co-transfected with pCMV-LnL1.1 using a 1:1 DNA:DNA ratio and 
fluorescence and luminescence intensities were measured 24 and 48 hours after transfection 
(Figure 2). These experiments showed that, while the luminescence intensity did not exhibit a 
discernible change between 24 and 48 hours, there was a marked increase in the GFP-Max 
fluorescence intensity over this same time period. This is likely a function of the maturation time 
required for the GFP fluorophore. Interestingly, following Metafectene-mediated transfection, the 
luminescence signal was much lower than anticipated. Therefore, to determine whether this effect 
was specific to Metafectene or a general property of cationic lipid reagents, we tested a series of 
cationic lipid-based transfection reagents.  
Specifically, we examined Metafectene Pro, Lipofectamine 2000 and linear PEI. In 
addition, we also assayed Turbofect, which utilizes a related cationic polymer-based formulation 
supplemented with histone protein. Because B cells are notoriously difficult to transfect, the 
transfection efficiency of pGFP-Max alone was assessed for each reagent using live cell 
fluorescence imaging before attempting co-transfection experiments. During these experiments, 
the total amount of pGFP-Max DNA was varied (while maintaining a 1:1 DNA:reagent ratio) in 
order to determine the amount of DNA necessary to achieve optimal transfection efficiency 
without adversely affecting cell viability (Figures 3, 4).   
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Figure 2. Time trial (24-48hr) Optimization Metafectene Pro.  Experimental conditions, including how 
long after transfection the measurements were taken, are indicated. GFP: pGFP-Max; pCMV: pCMV-
LnL1.1; pUC19: empty vector, used to maintain equivalent amounts of DNA across experiments.  A) 
Fluorescence intensity expressed in arbitrary units (AU). B) Luminescence intensity expressed in AU. Error 
bars represent the standard error. 
These experiments suggest that maximal transfection efficiency is achieved between 1 and 
2 µg of DNA for all of the reagents tested (Figure 3). Likewise, a marked decrease in viability was 
observed when > 2 µg of DNA was used (Figure 4). Only PEI, which did not exhibit a substantial 
decrease in viability until 4 µg of DNA was used, did not appear to follow this trend. Taken 
together, these results suggest that 1-2 µg of DNA is optimal for the liposome-based transfection 
reagents tested.  
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Figure 3. Optimization of Transfection Efficiencies: DNA Titration TK6 B cells were transfected with 
increasing amounts of DNA and transfection efficiencies were determined. In each experiment, the 
DNA:reagent ratio was maintained at 1:3. A) Metafectene Pro. B) Lipofectamine 2000. C) Turbofect. D) 
PEI. 
 
Figure 4. Optimization of Cell Viability: DNA Titration.  TK6 B cells were transfected as described in 
Figure 3. A) Metafectene Pro. B) Lipofectamine 2000. C) Turbofect. D) PEI. 
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The previous experiments suggested that higher liposome concentrations may adversely affect cell 
viability—and perhaps cell physiology at even lower concentrations. While the manufacturers 
suggest using a total DNA:reagent ratio of 1:3 as a starting point, the optimal conditions in our 
system had yet to be explored.  Therefore, we were curious to see if similar results would be 
obtained at lower DNA:reagent ratios. Each of the four reagents was thus analyzed at various total 
DNA:reagent ratios, with the total DNA remaining constant (Figure 5).  These data indicate that a 
1:1 DNA:reagent ratio yields  the  best results. 
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Figure 5.  DNA to Reagent Ratio Optimization for Liposome Reagents: Fluorescence Read.   2µg DNA 
(GFP) with transfection reagent at indicated ratio (m:v); 1:3 (2µg:6µl), 1:1 (2µg:2µl), 3:1 (2µg:0.5µl). A.) 
Metafectene Pro. B) Lipofectamine 2000. C) Turbofect. D) PEI. 
The usage of less reagent is beneficial to the fluorescence.  Since the cationic formulation 
appears to inhibit luciferase activity, it was imperative to see the effects of more luciferase with 
less transfection reagent.  We pursued this by analyzing various DNA:DNA ratios, specifically 
A. B. 
D. C. 
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weighing more toward luciferase (pCMV-nL1.1).  During these experiments, the total 
DNA:reagent ratio remained constant.  As expected, a reduction in pGFP-Max corresponds with a 
reduction in the fluorescence signal (Figure 6).  However, despite an approximately 9-fold increase 
in pCMV-LnL1.1 DNA, only a marginal increase in luciferase activity was observed (Figure 7).  
Thus, the optimal DNA:DNA ratio appears to be 1:1.  Importantly, during these experiments, 
Turbofect-mediated transfection resulted in the highest luminescence intensity while PEI exhibited 
the best fluorescence signal via co-transfection. 
 
 Figure 6.  Optimization of DNA to DNA Ratio: Fluorescence Read. Total DNA: reagent ratio remained 
constant (1:1) (2µg:2µl). DNA:DNA ratio varying at indicated ratio (m:m); 1:1 (1µg:1µg), 1:3 
(0.5µg:1.5µg), 1:9 (0.2µg:1.8µg). A) Metafectene Pro. B) Lipofectamine 2000. C) Turbofect. D) PEI. 
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Figure 7.  Optimization of DNA to DNA Ratio: Luminescence Read.  Total DNA: reagent ratio constant 
(1:1) (2µg:2µl). DNA:DNA ratio varying at indicated ratio (m:n); 1:1 (1µg:1µg), 1:3 (0.5µg:1.5µg), 1:9 
(0.2µg:1.8µg). A) Metafectene Pro. B) Lipofectamine 2000. C) Turbofect. D) PEI. 
4.2 Normalization of Luciferase Signal via GFP Co-transfection  
Next, with the transfection protocols for TK6 B cells established, the fluorescence and 
luciferase activity following liposome-mediated transfection could be measured in parallel to 
normalize the fluorescence/luminescence signal.  To this end, B cells were co-transfected with 
pGFP-Max and pCMV-LnL1.1, using pUC19 as an empty vector so that the total amount of DNA 
remained constant throughout. These results were consistent with previous co-transfection 
experiments using Metafectene Pro in TK6 B cells.  While Metafectene Pro and Lipofectamine 
2000 displayed decent fluorescence intensity, in each case low luciferase activity was observed 
(Figures 8-9). PEI exhibited the greatest fluorescence signal with a high transfection efficiency.  
However, just like Metafectene Pro and Lipofectamine 2000, there appeared to be quite a bit of 
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luciferase interference (Figure 9D).  In contrast, though cells transfected with Turbofect showed 
somewhat less fluorescence activity relative to those transfected with the other liposome-based 
reagents, they exhibited a consistent luminescence signal that was significantly higher than the 
other reagents (Figures 10-11).  These consolidated results confirmed the hypothesis that cationic 
lipid-based reagents interferes with luciferase activity, since Metafectene Pro, Lipofectamine 
2000, and PEI are of cationic lipid formulation and Turbofect is lipid/histone formulated.   
 
Figure 8.  Co-transfection via Metafectene Pro.  48 hour co-transfection GFP/pCMV-LnL1.1.  Total DNA: 
reagent ratio 1:1 (2µg:2µl) with a DNA:DNA ratio 1:1 (1µg:1µg). pUC19 used as empty vector for positive 
controls. A) Fluorescence read B) Luminescence read 
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Figure 9.  Co-transfection via Lipofectamine Pro.   48 hour co-transfection GFP/pCMV-LnL1.1.  Total 
DNA:reagent ratio 1:1 (2µg:2µl) with a DNA:DNA ratio 1:1 (1µg:1µg). pUC19 was used as empty vector 
for positive controls. A) Fluorescence read B) Luminescence read. 
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Figure 10:  Co-transfection via Turbofect.  48 hour co-transfection GFP/pCMV-LnL1.1.  Total DNA: 
reagent ratio 1:1 (2µg:2µl) with a DNA:DNA ratio 1:1 (1µg:1µg). Puc19 used as empty vector for positive 
controls. A) Fluorescence read B) Luminescence read  
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Figure 11:  Co-transfection via PEI. 48 hour co-transfection GFP/pCMV-LnL1.1.  Total DNA: reagent 
ratio 1:1 (2µg:2µl) with a DNA:DNA ratio 1:1 (1µg:1µg). Puc19 used as empty vector/filler for positive 
controls. A) Fluorescence read B) Luminescence read.  
To determine whether the liposome-based reagents only inhibit NLuc or whether the 
inhibition was a general phenomenon among luciferases, pCMV-LnL1.1 (NLuc) was compared to 
pGL3 encoding FLuc (Figure 12). These results are consistent with previous findings, with 
Turbofect again showing the least degree of inhibition with both luciferase/luciferin combinations. 
This was not due to properties intrinsic to the plasmids, since nucleofection resulted in robust 
luciferase and GFP signals (Figure 13). 
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Figure 12:  Luciferin Comparison Nano-luciferase vs Firefly Luciferase.  48 hour co-transfection via 
varying liposome reagents.  Total DNA:reagent ratio (1:1) (2µg:2µl) with DNA:DNA (1:1) (1µg:1µg). A) 
PCMV-LnL1.1 (NLuc) fluorescence read. B) PCMV-LnL1.1(NLuc) luminescence read. C) PGL3 (FLuc) 
fluorescence read. D) PGL3 (FLuc) luminescence read. 
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Figure 13:  Nucleofection (Lonza) Co-transfection. GFP: pCMV-LnL1.1. pUC19 used as empty vector 
for positive controls.  DNA:DNA 1:1 (0.2µg:0.2µg).  (-) Control cells were nucleofected with no DNA.  A) 
Fluorescence read. B) Luminescence read. 
Despite the relatively low luminescence signal obtained using liposome-based reagents, 
the low background luminescence resulted in an approximately 30-fold increase in transfected 
versus non-transfected cells. We hypothesized that this dynamic range would be sufficient to 
monitor changes in promoter activity, if differences in transfection efficiency between samples 
could be eliminated. Therefore, we asked whether GFP normalization would account for 
differences in transfection efficiency. To this end, transiently transfected TK6 B cells were diluted 
with untransfected TK6 B cells to simulate differences in transfection efficiency from 100% 
(undiluted) to 25% (diluted 1:3 with untransfected cells) efficiency. At each dilution, 
luminescence/fluorescence signal in TK6 B cells was measured and the luminescence signal 
normalized to the GFP fluorescence. During these studies, we focused on PEI- and Turbofct-
mediated transfection. We chose Turbofect because it exhibited the strongest luciferase activity. 
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Likewise, PEI was chosen because it consistently exhibited robust transfection efficiency with 
minimal cell death while, at the same time, resulting in strong fluorescence intensity These studies 
demonstrated that, even if the transfection efficiency varies, the fluorescence/luminescence signal 
will remain consistent when the corrected luminescence signal is normalized to fluorescence 
intensity (Figure 14-15). Importantly, normalization also appears to be allow comparisons over a 
range of luminescence intensities, as evidenced by nucleofection experiments (Figure 16).  
 
Figure 14:  Turbofect Co-transfection Dilution (transfected vs non-transfected cells). GFP: pCMV-
LnL1.1.  Total DNA: reagent 1:1 (2µg:2µl) with DNA:DNA ratio 1:1 (1µg:1µg).  A) Fluorescence read B) 
Luminescence read C) Transfection efficiency D) Corrected (corr’d) luminescence/fluorescence 
normalization ratio 
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Figure 15:  PEI co-transfection dilution (transfected vs non-transfected cells). GFP: pCMV-LnL1.1.  Total 
DNA: reagent 1:1 (2µg:2µl) with DNA:DNA ratio 1:1 (1µg:1µg).  A) Fluorescence read B) Luminescence 
read C) Transfection efficiency D) Corrected (corr’d) luminescence/fluorescence normalization ratio. 
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Figure 16:  Nucleofection (Lonza) Co-transfection Dilution (transfected vs non-transfected cells). GFP: 
pCMV-LnL1.1.  DNA:DNA ratio 1:1 (0.2µg:0.2µg).  A) Fluorescence read B) Luminescence read C) 
Transfection efficiency D) Corrected (corr’d) luminescence/fluorescence normalization ratio 
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Chapter 5 
Discussion and Future Directions 
In this study, we optimized B cell transfection conditions and detection via the liposome-
based reagents, Metafectene Pro, Lipofectamine 2000, Turbofect, and PEI. Peak fluorescence 
intensity was observed 48 hour after transfection while luminescence remained constant between 
24 and 48 hours post-transfection.  Both the maximum transfection efficiency and cell viability 
were observed between 1 and 2 µg of DNA. Likewise, a DNA:reagent ratio of 1:1 (2µg:2µl) and 
a DNA:DNA (pCMV-LnL1.1:GFP) ratio of 1:1 was shown to result in maximal signal using all 
liposome-based reagents tested..  
Interestingly, under our optimized liposome co-transfection conditions, all liposome-based 
transfection reagents exhibited substantially reduced luminescence signal relative to that observed 
using nucleofection. Nonetheless, PEI and Turbofect exhibited 20- to 30-fold changes in 
luminescence intensity relative to untransfected controls and, due to their advantageous attributes, 
were further pursued.  Nucleofection was employed to the cells to compare the commonly used 
liposome reagents, to a specialized transfection method.  In respect to fluorescence activity, the 
signal remained constant for cells transfected via liposome reagents and nucleofection.  On the 
other hand, nucleofection luciferase activity was outstandingly prominent in comparison to 
Turbofect and PEI.  The transfection efficiency dilution for all (Turbofect; PEI; nucleofection) 
methods results lead to the overarching goal; the normalization of the luciferase signal no matter 
the transfection efficiency.  
These findings are significant and can be viewed as a two-edged sword.  Not only has the 
transfection of B cells via liposome-based reagents and nucleofection been optimized, but the 
normalization of the luciferase signal has led to a cost effective means of transfection and detection 
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in B cells, which are notoriously difficult to transfect.  Cost plays a significant role in research, 
and is often that certain studies are not fully pursued.  On a per run basis, nuclofection is very 
effective but is also ~10x more expensive than Turbofect and ~15x more expensive than PEI 
(excluding the cost of the nucleofection system, itself).  Thus, the development of a robust, 
generalizable normalization method based on co-transfected GFP enables the use of much less 
expensive liposome-based reagents.  
The co-transfection of GFP with luciferase will help normalize the luciferase signal to 
investigate p53 promoters stimulated by DEB, the most potent metabolite of 1, 3-butadiene (BD), 
an environmental chemical found in petrochemical industrial areas. BD is a known mutagen and 
human carcinogen, and possesses multi-systems organ toxicity (Yadavilli, Martinez-Ceballos et 
al. 2007). In future studies, the comparison of another promoter with the luciferin, may give insight 
into whether a change in promoters will increase or decrease luciferase activity via liposome.  
Furthermore, optimization of the co-transfection protocol may open the door for other types of 
cell-based assays. For instance, the apoptotic pathway of B cells can be analyzed using 
fluorescence resonance energy transfer (FRET)- or BRET-based biosensors.  DEB-induced cells 
undergo apoptosis not necrosis.  Apoptosis has three phases; initiation, commitment, and 
execution.  The initiation phase was discovered and demonstrates the cytokine c release from the 
mitochondria, more specifically, the mitochondrial transition pore.  This has yet to be seen in TK6 
B cells, and the question of do B cells undergo an alternate apoptotic pathway has yet to be 
answered.   
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